Curriculum Vitae

Name: Dr Michal ROLINSKI
Address: Movement Neuroscience Research Group
Institute of Clinical Neurosciences, University of Bristol
Level 1, Learning and Research Building,
Southmead Hospital, Bristol BS10 5NB

Email: michal.rolinski@bristol.ac.uk

Nationality: British and Polish

Current employment:

2017- present NIHR Academic Clinical Lecturer in Neurology

Academic Qualifications:

2017 DPhil: Clinical Neuroscience, University of Oxford

Thesis: Clinical and Neuroimaging Biomarkers of Early and Prodromal Parkinson's Disease

2011 Membership of the Royal College of Physicians (London)

2008 BM BCh (with distinction): University of Oxford

2005 BA (Hons): Medical Sciences, University of Oxford

Academic leadership:

2018 – present Deputy Research Lead, Movement Disorders Health Integration Team (MOVE-hIT)

Honours, awards:

2015 Young Investigator Award from the World Association of Sleep Medicine and the Parkinson Non-motor Study Group

2014 Parkinson's UK Travel Award

2009 European Federation of Neurological Societies Travel Bursary

2008 Warren Trust Scholarship (The Queen's College, Oxford)

2003 Michel Exhibition (The Queen's College, Oxford)

Professional Affiliations:

Movement Disorders Society

British Neuroscience Association

The South West Neuroscience Association

International RBD Study Group

Member of the Royal College of Physicians

Major Invited Talks and Lectures:

Sixth Annual Parkinson's Disease Forum, Bristol, February 2017

World Congress on Sleep Medicine, Seoul, South Korea, March 2015

International RBD Study Group Meeting, Helsinki, Finland, September 2014

World Congress of Neurology, Bangkok, Thailand, October 2009

The Royal Society of Medicine, London, March 2009

Major and Current Grants:

2019-2012	Academy of Medical Sciences Starter Grants for Clinical Lecturers: Tracking motoric progression in established and prodromal Parkinson's disease (Rolinski (PI))	£29,512
2019-2012	Wellcome Trust Population Award: White matter microstructural biomarkers in prodromal Parkinson's disease (Rolinski (Co-PI), Lawrence (Co-PI), Whone and Jones)	£42,900
2019-2021	NIHR RfPB: PLanning Appropriate Nocturia Evaluation and Treatment (PLANET); an interdisciplinary consensus (Drake (PI) and others including Rolinski)	£149,978
2018-2020	David Telling Trust: Progression of Neurodegeneration in Patients with Prodromal Parkinson's Disease (Rolinski (PI) and Whone)	£22,730
2015-2018	GE Healthcare project grant: Dopaminergic correlates of resting state fMRI activity in REM sleep behaviour disorder (Hu (PI) and others including Rolinski)	£25,000 and 50 doses of DaTSCAN
2012-2015	NIHR Oxford Biomedical Centre Clinical Training Research Fellowship: Imaging biomarkers in pre-motor Parkinson's disease (Rolinski)	£168,000

Selected Publications:

Baig F, Kelly M, Lawton M, Rolinski M, et al. Impulse control disorders in Parkinson's and RBD - a longitudinal study of severity. Neurology (in press)

Postuma RB et al. Risks and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder: a multicentre study. Brain. 2019;142(3):744-759

Arora S, Baig F, Lo C, Barber TR, Lawton M, Zhan A, Rolinski M, et al. Smartphone motor testing to distinguish idiopathic REM sleep behaviour disorder, controls and PD. Neurology 2018; 91(16):e1528-e1538

Smith AM, Depp C, Ryan BJ, Johnson GI, Alegre-Abarrategui J, Evetts S, Rolinski M, et al. Mitochondrial dysfunction and increased glycolysis in prodromal and early Parkinson's blood cells. Mov Disord. 2018; 33(10):1580-1590

Klein JC, Rolinski M, Griffanti L, Szewczyk-Krolikowski K, Baig F, Ruffmann C, et al. Cortical structural involvement and cognitive dysfunction in early Parkinson's disease. NMR Biomed. 2018;31(4):e3900.

Gan-Or Z, Montplaisir JY, Ross JP, Poirier J, Warby SC, Arnulf I, et al. The dementia-associated APOE epsilon4 allele is not associated with rapid eye movement sleep behavior disorder. Neurobiol Aging. 2017;49:218 e13- e15.

Barber TR, Lawton M, Rolinski M, Evetts S, Baig F, Ruffmann C, et al. Prodromal Parkinsonism and Neurodegenerative Risk Stratification in REM Sleep Behavior Disorder. Sleep. 2017;40(8).

Rolinski M, Zokaei N, Baig F, Giehl K, Quinnell T, Zaiwalla Z, et al. Visual short-term memory deficits in REM sleep behaviour disorder mirror those in Parkinson's disease. Brain. 2016;139(Pt 1):47-53.

Rolinski M, Griffanti L, Piccini P, Roussakis AA, Szewczyk-Krolikowski K, Menke RA, et al. Basal ganglia dysfunction in idiopathic REM sleep behaviour disorder parallels that in early Parkinson's disease. Brain. 2016;139(Pt 8):2224-34.

Griffanti L, Rolinski M, Szewczyk-Krolikowski K, Menke RA, Filippini N, Zamboni G, et al. Challenges in the reproducibility of clinical studies with resting state fMRI: An example in early Parkinson's disease. Neuroimage. 2016;124(Pt A):704-13.

Fairfoul G, McGuire LI, Pal S, Ironside JW, Neumann J, Christie S, et al. Alpha-synuclein RT-QuIC in the CSF of patients with alpha-synucleinopathies. Ann Clin Transl Neurol. 2016;3(10):812-8.

Rolinski M, Griffanti L, Szewczyk-Krolikowski K, Menke RA, Wilcock GK, Filippini N, et al. Aberrant functional connectivity within the basal ganglia of patients with Parkinson's disease. Neuroimage Clin. 2015;8:126-32.

Baig F, Lawton M, Rolinski M, Ruffmann C, Nithi K, Evetts SG, et al. Delineating nonmotor symptoms in early Parkinson's disease and first-degree relatives. Mov Disord. 2015;30(13):1759-66.

Szewczyk-Krolikowski K, Menke RA, Rolinski M, Duff E, Salimi-Khorshidi G, Filippini N, et al. Functional connectivity in the basal ganglia network differentiates PD patients from controls. Neurology. 2014;83(3):208-14.

Rolinski M, Szewczyk-Krolikowski K, Tomlinson PR, Nithi K, Talbot K, Ben-Shlomo Y, et al. REM sleep behaviour disorder is associated with worse quality of life and other non-motor features in early Parkinson's disease. J Neurol Neurosurg Psychiatry. 2014;85(5):560-6.

Hu MT, Szewczyk-Krolikowski K, Tomlinson P, Nithi K, Rolinski M, Murray C, et al. Predictors of cognitive impairment in an early stage Parkinson's disease cohort. Mov Disord. 2014;29(3):351-9.

Rolinski M, Fox C, Maidment I, McShane R. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease. Cochrane Database Syst Rev. 2012(3):CD006504.